Statements (155)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:cancer_treatment
gptkb:immunotherapy |
| gptkbp:administered_by |
injection
intravenous injection |
| gptkbp:advocacy |
informed consent required
engaged in outreach efforts |
| gptkbp:analysis |
statistical methods used
|
| gptkbp:benefits |
improves overall survival
enhanced anti-tumor immunity enhanced tumor response improves survival rates |
| gptkbp:biomarker_study |
ongoing
|
| gptkbp:business_model |
approved by ethics board
adhering to guidelines |
| gptkbp:can_be_combined_with |
checkpoint inhibitors
chemotherapy |
| gptkbp:clinical_trial |
gptkb:Medi_Wound_Ltd.
gptkb:Medigene_AG gptkb:2018 Phase 1 pending Phase 2 randomized controlled trials multiple sites randomized controlled trial various sites globally overall survival not yet published Phase 2 planned pending publication multi-center study |
| gptkbp:clinical_trial_phase_details |
Phase 1 trials ongoing
|
| gptkbp:clinical_trials_location |
gptkb:Europe
gptkb:United_States |
| gptkbp:collaboration |
academic institutions
|
| gptkbp:collaborations |
academic institutions
biotech companies |
| gptkbp:collaborator |
various research institutions
various academic institutions |
| gptkbp:collection |
real-time monitoring
prospective study |
| gptkbp:combination_therapy_with |
checkpoint inhibitors
|
| gptkbp:developed_by |
gptkb:Medi_Wound_Ltd.
gptkb:Medigene_AG Medi Rox |
| gptkbp:dosage_form |
weekly
based on clinical trial results based on patient response |
| gptkbp:duration |
varies by protocol
varies by trial |
| gptkbp:eligibility |
various cancer types
advanced colorectal cancer |
| gptkbp:feedback |
generally positive
ongoing assessment |
| gptkbp:finale_date |
overall response rate
progression-free survival |
| gptkbp:funding |
gptkb:venture_capital
public and private sources government grants |
| gptkbp:future_prospects |
exploring combination therapies
expanding indications promising in melanoma therapy |
| gptkbp:has_research_focus |
multidisciplinary group
|
| https://www.w3.org/2000/01/rdf-schema#label |
MRx0518
|
| gptkbp:impact |
potential to change treatment landscape
|
| gptkbp:indication |
solid tumors
|
| gptkbp:invention |
patented
|
| gptkbp:investigates |
safety and efficacy
under investigation ongoing trials |
| gptkbp:investment |
high due to melanoma prevalence
melanoma treatment market |
| gptkbp:is_effective_against |
to be determined
|
| gptkbp:is_monitored_by |
clinical assessments
regular check-ups regular assessments ongoing during trials |
| gptkbp:is_tested_for |
Phase 1
PD-L1 expression immune activation Phase 1/2 trial |
| gptkbp:mechanism_of_action |
stimulates immune response
activates T-cells |
| gptkbp:notable_work |
to be published
preliminary data available |
| gptkbp:objective |
evaluate safety
|
| gptkbp:origin |
gptkb:Biology
derived from bacterial components |
| gptkbp:pathway |
FDA approval process
|
| gptkbp:patient_eligibility_criteria |
advanced melanoma patients
|
| gptkbp:patient_population |
diverse demographics
advanced cancer patients |
| gptkbp:project |
clinical development
|
| gptkbp:provides_guidance_on |
gptkb:hospital
|
| gptkbp:publication |
peer-reviewed journals
|
| gptkbp:recruitment |
ongoing
specific inclusion/exclusion criteria |
| gptkbp:regulatory_compliance |
gptkb:Clinical_Trials
not approved not yet approved |
| gptkbp:related_products |
yes
IND application filed IND application submitted filed with FDA |
| gptkbp:research |
randomized controlled trial
|
| gptkbp:research_areas |
oncology
cancer immunotherapy |
| gptkbp:research_focus |
oncology
solid tumors cancer immunotherapy |
| gptkbp:research_output |
ongoing
preliminary results |
| gptkbp:research_phase |
early phase
|
| gptkbp:response_time |
under investigation
|
| gptkbp:route_of_administration |
subcutaneous
systemic intratumoral intratumoral injection |
| gptkbp:safety_features |
under evaluation
|
| gptkbp:safety_measures |
adverse event reporting
|
| gptkbp:scientific_goals |
improve patient outcomes
|
| gptkbp:serves |
gptkb:Oncology
|
| gptkbp:service_frequency |
weekly
once a week |
| gptkbp:side_effect |
mild to moderate
monitored closely |
| gptkbp:sponsor |
Medi Rox
|
| gptkbp:status |
gptkb:Clinical_Trials
investigational |
| gptkbp:target_audience |
patients with lung cancer
patients with advanced melanoma patients with advanced prostate cancer patients with breast cancer patients with colorectal cancer |
| gptkbp:targets |
tumor microenvironment
tumor cells |
| gptkbp:treatment |
standardized procedures
chemotherapy under investigation assessed regularly tracked over time monotherapy tumor reduction assessed through trials monitored through imaging standardized guidelines |
| gptkbp:treatment_evaluation |
based on clinical data
|
| gptkbp:treatment_innovation |
new therapeutic approach
|
| gptkbp:type |
gptkb:immunotherapy
therapeutic vaccine |
| gptkbp:type_of |
gptkb:immunotherapy
|
| gptkbp:used_for |
gptkb:Oncology
|
| gptkbp:used_in |
cancer patients
|
| gptkbp:bfsParent |
gptkb:4_D_Pharma
|
| gptkbp:bfsLayer |
6
|